Navigation Links
BioLineRx Reports Third Quarter 2013 Financial Results
Date:11/13/2013

BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Secur
'/>"/>

SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
2. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
3. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
7. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
8. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
9. BioLineRx to Present at 15th International Celiac Disease Symposium
10. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
11. BioLineRx Appoints B. J. Bormann to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) ... January 26, 2011.  The company will host a webcast the ... EST. Earnings Release:   Hill-Rom,s Fiscal 2011 ... 2010, will be issued to the public after the close ...
... Amarin Corporation plc (Nasdaq: AMRN ) (the "Company"), ... today announced that it has completed its previously announced underwritten ... to the public of $7.60 per ADS. Due ... the company sold a total of 13,800,000 ADSs in the ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2Amarin Announces Successful Completion of Offering of American Depositary Shares 2Amarin Announces Successful Completion of Offering of American Depositary Shares 3
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... reputation for being highly toxic, but when used in the ... to offer potential health benefits in a range of issues, ... compound (AP39), designed and made at the University of Exeter, ... of very small amounts of the substance to the right ... have already found that the compound protects mitochondria the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... a way to predict whether women with ductal carcinoma in ... cancer are at risk of developing more invasive tumors ... women with DCIS will have the opportunity to be more ... will have much more information, so they can better know ...
... for Radiation Oncology (ASTRO) has released its Emerging ... body radiotherapy (SBRT) in lung cancer treatment. SBRT ... focused radiation beams to target a well-defined tumor ... planning and precise treatment setup to deliver the ...
... release is available in French . , Ottawa, ... ideas amongst researchers is a fundamental element in turning knowledge ... Thanks to the newly launched PubMed Central Canada (PMC Canada), ... archive of published Canadian health research. PMC Canada ...
... researchers find , WEDNESDAY, April 28 (HealthDay News) -- ... lung disease caused by cystic fibrosis: Which comes first, ... beginning to answer that question, and it looks like ... an assistant professor of internal medicine at the University ...
... ... Air” in HuffPost Living , ... (PRWEB) April 28, 2010 -- Huffington Post blogger and radio host Kathleen ... radio program, The Kathleen Show ., , ,Each week in The Huffington Post ...
... ... , ... 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and ... care programs in connection with its marketing and promotional practices for the blockbuster atypical ...
Cached Medicine News:Health News:Breakthrough method predicts risk of invasive breast cancer 2Health News:Breakthrough method predicts risk of invasive breast cancer 3Health News:Canada joins international network providing free access to health research 2Health News:Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease 2Health News:The Kathleen Show Launches Weekly Audio Blog on The Huffington Post 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 3
Microscissors : Horizontal Scissors...
Disposable Microscissors: Vertical, 90...
Microscissors: Eckardt Vertical Retinomy Scissors...
... the original and very popular ... for cutting in the vertical ... curved tips allow greater versatility ... retlna. Tip is shaped like ...
Medicine Products: